Clinical Trials Logo

Pertussis clinical trials

View clinical trials related to Pertussis.

Filter by:

NCT ID: NCT00831311 Completed - Tetanus Clinical Trials

Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® PEDIATRICO in Argentinean Infants

Start date: October 2004
Phase: Phase 2
Study type: Interventional

Primary Objective: - To demonstrate that the immune response of the DTaP-IPV-Hep B-PRP~T is non-inferior for all valences to those of the association of PENTAXIM™ and ENGERIX B® PEDIATRICO one month after a three-dose primary series. Secondary Objectives: - To describe in each group the immunogenicity parameters one month after the three-dose primary series. - To describe safety profile after each vaccination in both groups.

NCT ID: NCT00828555 Completed - Pertussis Clinical Trials

Effectiveness of a Vaccination Program in the Community Ob/Gyn Setting

Start date: November 2008
Phase: N/A
Study type: Observational

PURPOSE To develop, implement, and evaluate the effectiveness of a program designed to assist community Ob/Gyns in vaccinating adolescent and adult women against vaccine-preventable diseases. SPECIFIC AIMS 1. Determine the feasibility of implementing a successful vaccination program for adolescent and adult women in Ob/Gyn offices by direct assessment of medical personnel & office staff on their: - Attitudes towards vaccination of women against preventable diseases - Perceived barriers to implementing a program to vaccinate women in their offices - Ideas on how to overcome barriers to successful program implementation - Current vaccination practices and office-specific administrative processes 2. Design & implement a program for Ob/Gyns to vaccinate women against human papillomavirus, influenza, & pertussis 3. Determine the effectiveness of the vaccination program based on - Pre- and post-program vaccination rates - Program satisfaction amongst Ob/Gyn providers and office staff - Willingness to continue and possibly extend the program to additional vaccines 4. Quantify the level of support and resources needed to develop and implement the vaccination program

NCT ID: NCT00804284 Completed - Tetanus Clinical Trials

Database Surveillance Safety Study of PENTACEL® Vaccine

Start date: September 2008
Phase: N/A
Study type: Observational

The objective for this study is to characterize the safety profile of PENTACEL® vaccine for identification of potential vaccine-related adverse events not currently associated with PENTACEL® vaccine administration.

NCT ID: NCT00802867 Completed - Tetanus Clinical Trials

Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™

Start date: February 2004
Phase: Phase 4
Study type: Interventional

Objectives: - To present the rates of adverse reactions after a dose of DAPTACEL® vaccine administered to children 4 to 6 years of age who have previously received four doses of PENTACEL™ vaccine. - To present immunogenicity before and after a single dose of DAPTACEL® vaccine administered to children 4 to 6 years of age who have previously received four doses of PENTACEL™ vaccine.

NCT ID: NCT00797511 Completed - Tetanus Clinical Trials

Immunogenicity and Safety of Adacel Polio Vaccine

Start date: November 2008
Phase: Phase 3
Study type: Interventional

The present study is designed to meet the requirements of the Taiwanese Health Authorities for registration of ADACEL POLIO in Taiwan. Subjects will receive one dose of the study vaccine at 6 to 8 years of age. Blood samples will be taken for antibody titration. The expected total duration of follow-up for each subject will be 28 days.

NCT ID: NCT00777257 Completed - Tetanus Clinical Trials

Study of Menactra® in US Adolescents When Administered Concomitantly With Tdap Vaccine

Start date: April 2005
Phase: Phase 4
Study type: Interventional

The purpose of this study was to evaluate the immunogenicity and safety of the concomitant administration of Menactra® vaccine and Tdap vaccine in adolescents aged 11 to 17 years. Primary Objective: To determine whether concomitant administration of two vaccines, Tdap and Menactra®, induces antibody responses that are similar to those observed when each vaccine is given separately. Secondary Objective: To compare the rates of injection site reactions at the Tdap injection site after Tdap and Menactra® vaccines are administered concomitantly to the corresponding rates of reactions when Tdap vaccine is administered alone.

NCT ID: NCT00772928 Completed - Tetanus Clinical Trials

Study of the Effect of Pneumococcal Conjugate Vaccine (PCV) on Immunogenicity of Pentacel™

Start date: October 2003
Phase: Phase 3
Study type: Interventional

This study is designed to evaluate in a controlled manner the effect of Prevnar® on the immune responses of Pentacel™ Primary Objective - Stage I: To compare the immune responses elicited by an infant series of Pentacel™ when given at different times from or concurrently with a Pneumococcal conjugate vaccine (Prevnar®). Primary Objective - Stage II: To compare the immune responses elicited by a 4th dose of Pentacel™ when given at different times from or concurrently with Prevnar®.

NCT ID: NCT00772369 Completed - Tetanus Clinical Trials

Retrospective Survey of Safety of Fourth Dose Pentacel® in Children

Start date: September 2003
Phase: Phase 4
Study type: Observational

The purpose of this survey is to collect selected safety data. Primary Objective: To collect selected safety data at 6 months following the 4th dose of the Pentacel® series.

NCT ID: NCT00712959 Completed - Tetanus Clinical Trials

Immune Responses in Adults to Revaccination With ADACEL® 10 Years After a Previous Dose

Start date: June 2008
Phase: Phase 4
Study type: Interventional

The purpose of this study is to collect additional immunogenicity and safety data on re-dosing with Tdap vaccine (ADACEL®) in a continuing effort to address the public health need to establish broader population immunity against pertussis, as well as diphtheria and tetanus. Primary Objective: - To assess immune response to Tdap vaccine (ADACEL®) one month after booster vaccination.

NCT ID: NCT00707148 Completed - Tetanus Clinical Trials

Pertussis Vaccine in Healthy Pregnant Women

Start date: January 2009
Phase: Phase 1
Study type: Interventional

The purpose of this study is to look at the safety and immunogenicity of a combination vaccine that includes tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap). The study will be conducted in 48 pregnant women and 32 non-pregnant women. Safety of the newborn infant and the effect of the mother's vaccination on the infants' immune responses prior to vaccinating infants with another combination vaccine to protect against diphtheria, tetanus, and pertussis will be evaluated. Participants will be 18-45 years old. Pregnant volunteers will be 30-32 weeks pregnant and at a low risk for pregnancy complications. Pregnant volunteers will receive 2 injections (1 vaccine and 1 placebo, inactive substance); non-pregnant volunteers will receive 1 injection of vaccine. Blood samples will be collected from the mother and infant, along with the baby's growth measurements. Participation for mother infant pairs is about 15 months and about 7 months for non-pregnant women.